Physiological effects of Calprotectin and B Cell activating factor in COVID-19 Patients
Keywords:Calprotectin, B Cell Activating Factor, C-Reactive Protein, COVID-19
Objectives: This study set out to determine how Calprotectin and B cell activating factor contributes to early COVID-19 patient severity prediction.
Methods: The study included 25 healthy controls and 52 patients with SARS-COV2 infection who were clinically diagnosed with COVID-19 illness and were between the ages of 23 and 35. The serum levels of CALP and BAFF were measured using the ELISA method. To gauge CRP levels, an immunoturbidometric assay was performed.
Results: Variations in serum levels of CALP and BAFF were found to be statistically insignificant in the study (P=0.7109 & P=0.7575, respectively). When compared to the control group (103.95±36.67 ng/mL; 403.03±1.03), COVID-19 patients had non-significantly raised levels of CALP and BAFF (106.5±4.67 ng/mL; 436.9±12.77 pg/mL, respectively). According to ROC curve analysis, the area under the receiver operating characteristics curve (AUC) for CALP and BAFF was (0.5170) and (0.5259), respectively. (r=0.6923; P=0.0001). There was a significant positive correlation between serum CALP and BAFF levels. The connection between serum CRP levels and CALP (r=0.3010; P=0.1271) and BAFF levels (r=0.2912; P=0.1406) was insignificantly positive.
Conclusion: The current study's findings suggested that serum CALP and BAFF concentrations were increased in COVID-19 patients, suggesting that these inflammatory markers may be helpful indicators of the severity of COVID-19.
García de Guadiana-Romualdo, L. et al. Circulating levels of Calprotectin, a signature of neutrophil activation in prediction of severe respiratory failure in COVID-19 patients: a multicenter, prospective study (CalCov study). Inflammation Research 71, 57-67 (2022).
Guan, W.-j. et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine 382, 1708-1720 (2020).
Machhi, J. et al. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. Journal of Neuroimmune Pharmacology 15, 359-386 (2020).
Chang, S. E. et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nature communications 12, 1-15 (2021).
van Kampen, J. J. et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nature communications 12, 1-6 (2021).
Ortega, N. et al. Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. Nature communications 12, 1-10 (2021).
Udeh, R., Advani, S., de Guadiana Romualdo, L. G. & Dolja-Gore, X. Calprotectin, an emerging biomarker of interest in COVID-19: a systematic review and meta-analysis. Journal of clinical medicine 10, 775 (2021).
Silvin, A. et al. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell 182, 1401-1418. e1418 (2020).
Jukic, A., Bakiri, L., Wagner, E. F., Tilg, H. & Adolph, T. E. Calprotectin: from biomarker to biological function. Gut 70, 1978-1988 (2021).
Wang, L. et al. B cell activating factor regulates periodontitis development by suppressing inflammatory responses in macrophages. BMC oral health 21, 1-15 (2021).
Yang, S.-C., Tsai, Y.-F., Pan, Y.-L. & Hwang, T.-L. Understanding the role of neutrophils in acute respiratory distress syndrome. Biomedical Journal 44, 439-446 (2021).
Veras, F. P. et al. SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology. Journal of Experimental Medicine 217 (2020).
Shi, H. et al. Neutrophil calprotectin identifies severe pulmonary disease in COVID‐19. Journal of leukocyte biology 109, 67-72 (2021).
Nascimento, M. et al. B-cell activating factor secreted by neutrophils is a critical player in lung inflammation to cigarette smoke exposure. Frontiers in Immunology 11, 1622 (2020).
Zuo, Y. et al. Neutrophil extracellular traps in COVID-19. JCI insight 5 (2020).
Hanssen, N. M., Spaetgens, B., Nagareddy, P. R. & Murphy, A. J. DAMPening mortality in COVID-19: therapeutic insights from basic cardiometabolic studies on S100A8/A9. Circulation 143, 971-973 (2021).
Cherubini, F., Cristiano, A., Valentini, A., Bernardini, S. & Nuccetelli, M. Circulating Calprotectin as a supporting inflammatory marker in discriminating SARS-CoV-2 infection: an observational study. Inflammation Research 70, 687-694 (2021).
Chen, L. et al. Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Cellular & molecular immunology 17, 992-994 (2020).
Kaya, T. et al. Serum calprotectin as a novel biomarker for severity of COVID-19 disease. Irish Journal of Medical Science (1971-) 191, 59-64 (2022).
Mahler, M., Meroni, P.-L., Infantino, M., Buhler, K. A. & Fritzler, M. J. Circulating calprotectin as a biomarker of COVID-19 severity. Expert review of clinical immunology 17, 431-443 (2021).
Bauer, W. et al. Outcome prediction by serum calprotectin in patients with COVID-19 in the emergency department. Journal of Infection 82, 84-123 (2021).
Tomar, B., Anders, H.-J., Desai, J. & Mulay, S. R. Neutrophils and neutrophil extracellular traps drive necroinflammation in COVID-19. Cells 9, 1383 (2020).
Romand, X. et al. Systemic Calprotectin and chronic inflammatory rheumatic diseases. Joint Bone Spine 86, 691-698 (2019).
Wirtz, T. H. et al. Association of serum calprotectin concentrations with mortality in critically ill and septic patients. Diagnostics 10, 990 (2020).
Kunutsor, S. K. et al. Plasma calprotectin and risk of cardiovascular disease: Findings from the PREVEND prospective cohort study. Atherosclerosis 275, 205-213 (2018).
Wang, Q., Chen, W. & Lin, J. The Role of Calprotectin in rheumatoid arthritis. Journal of translational internal medicine 7, 126-131 (2019).
Yurtsever Kum, N. et al. Elevated serum calprotectin as an inflammatory marker in obstructive sleep apnea. CRANIO®, 1-7 (2020).
Candar, T., Baklacı, D., Kuzucu, İ. & Kayabaşı, S. A proinflammatory marker in chronic rhinosinusitis: serum calprotectin. Acta Biochimica Polonica (2020).
Do, R. K. G. & Chen-Kiang, S. Mechanism of BLyS action in B cell immunity. Cytokine & growth factor reviews 13, 19-25 (2002).
Schneider, P. & Tschopp, J. BAFF and the regulation of B cell survival. Immunology letters 88, 57-62 (2003).
Oliviero, B. et al. Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. Journal of hepatology 55, 53-60 (2011).
Das, A. et al. IL-10–producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. The Journal of Immunology 189, 3925-3935 (2012).
Wang, K. et al. Overexpression of Fc receptor-like 1 associated with B-cell activation during hepatitis B virus infection. Brazilian Journal of Medical and Biological Research 45, 1112-1118 (2012).
Toubi, E. et al. Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. Journal of autoimmunity 27, 134-139 (2006).
McNamara, P. et al. Respiratory syncytial virus infection of airway epithelial cells, in vivo and in vitro, supports pulmonary antibody responses by inducing expression of the B cell differentiation factor BAFF. Thorax 68, 76-81 (2013).
Ittah, M. et al. Induction of B cell-activating factor by viral infection is a general phenomenon, but the types of viruses and mechanisms depend on cell type. Journal of innate immunity 3, 200-207 (2011).
Rahman, Z. S. & Manser, T. B cells expressing Bcl-2 and a signaling-impaired BAFF-specific receptor fail to mature and are deficient in the formation of lymphoid follicles and germinal centers. The Journal of Immunology 173, 6179-6188 (2004).
Sutherland, A. P. et al. BAFF augments certain Th1-associated inflammatory responses. The Journal of Immunology 174, 5537-5544 (2005).
Nardelli, B. et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood, The Journal of the American Society of Hematology 97, 198-204 (2001).
Scapini, P. et al. G-CSF–stimulated neutrophils are a prominent source of functional BLyS. The Journal of experimental medicine 197, 297-302 (2003).
Zhu, J. et al. BlyS is up-regulated by hypoxia and promotes migration of human breast cancer cells. Journal of Experimental & Clinical Cancer Research 31, 1-7 (2012).
Jablonska, E. et al. Overexpression of B cell-activating factor (BAFF) in neutrophils of oral cavity cancer patients—preliminary study. Neoplasma 58, 211 (2011).
Fragioudaki, M. et al. Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma. Leukemia Research 36, 1004-1008 (2012).
Koizumi, M. et al. Increased B cell-activating factor promotes tumor invasion and metastasis in human pancreatic cancer. PloS one 8, e71367 (2013).
Liang, W. et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA internal medicine 180, 1081-1089 (2020).
How to Cite
Copyright (c) 2023 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.